指南与共识冠心病

ESC指南对早发缺血性心脏病一级预防的识别改善

Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines.
指南 / 共识 · Heart · 2023-03-10

基于ePARIS注册中2757例首次STEMI患者,比较2021、2019、2016版ESC/EAS指南对年轻成人一级预防他汀资格的识别。2021版使<55岁患者一级预防他汀资格达62.5%,远高于2016版17%和2019版18%。二级预防中仅25%年轻患者符合PCSK9i资格。

要点

  • 2021版ESC指南使<55岁首次STEMI前他汀一级预防资格达62.5%。
  • 2016和2019版指南下<55岁患者他汀资格仅17%和18%。
  • 首次STEMI后<55岁患者仅25%符合PCSK9i二级预防资格。

核心结论

  • 2021版ESC指南较既往版本显著提高年轻个体首次STEMI前的一级预防他汀识别。
  • 二级预防中多数年轻患者未达推荐LDL-C水平,但仅四分之一符合PCSK9i资格。

研究设计与样本

  • 基于ePARIS注册2010至2018年2757例首次STEMI患者,按年龄<55、55-65和>65岁分组。
  • 使用SCORE2评估2021版与2019、2016版ESC/EAS指南下的一级预防他汀资格及二级预防PCSK9i资格。

主要发现

  • 2021版指南下<55岁患者一级预防他汀资格为62.5%,与较年长组相似。
  • 2016和2019版指南下<55岁患者他汀资格分别为17%和18%,55-65岁组为41%和35%,>65岁组为19%和72%,p<0.01。
  • 首次STEMI后<55岁患者PCSK9i资格为25%,55-65岁组为23.2%,>65岁组为15%。

关键数值与推荐

  • 2021版ESC/EAS指南:<55岁患者一级预防他汀资格62.5%。
  • 2016版指南:<55岁、55-65岁、>65岁患者他汀资格分别为17%、41%、19%。
  • 2019版指南:<55岁、55-65岁、>65岁患者他汀资格分别为18%、35%、72%。
  • 二级预防PCSK9i资格:<55岁25%,55-65岁23.2%,>65岁15%。

临床怎么用

  • 对年轻成人应依据2021版ESC/EAS指南评估一级预防他汀资格,以提高首次STEMI前识别。
  • 年轻STEMI后患者需强化降脂以达推荐LDL-C目标,但仅约四分之一符合PCSK9i资格。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if the changes in the European Society Cardiology/European Atherosclerotic Society (ESC/EAS) guidelines improved the identification for primary prevention therapy in young adults at risk of a premature myocardial infarction. METHODS: Patients admitted for a first ST-segment elevation myocardial infarction (STEMI) in the ePARIS registry (n=2757) between 2010 and 2018 were classified by age: <55, 55-65 and >65 years old. Using Systematic Coronary Risk Estimation 2, we evaluated whether patients would have been detected and treated with primary prevention statins before their first STEMI based on the 2021 EAS/ESC guidelines versus 2019 and 2016 guidelines. Eligibility for intensive proprotein convertase subtilisin/kexin type 9 (PCSK9i) in secondary prevention was also assessed. RESULTS: Following 2021 ESC guidelines, 62.5% of individuals aged <55 years old would have been eligible for statins before their first STEMI, similarly to older age categories. In comparison, only 17% and 18% of young individuals would have been eligible for primary prevention statins prior to their first STEMI with 2016 and 2019 guidelines, compared with group 55-65 years (41% and 35%) and >65 years old (19% and 72%), p<0.01. After their first STEMI, 25% of patients <55 years would be eligible for PCSK9i, compared with 23.2% and 15% in patients aged 55-65 years and >65 years. CONCLUSIONS: The 2021 ESC guidelines allowed a much better detection of young individuals before their first STEMI than prior ESC guidelines. In secondary prevention, most of young individuals did not reach low-density lipoprotein cholesterol levels recommended, but only one quarter would be eligible for PCSK9i.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Zeitouni, Sulman, Silvain, et al. Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines. Heart. 2023. PMID: 36270781. doi:10.1136/heartjnl-2022-321688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。